CMS Proposed Rule Aims to Foster More Medicaid Value-Based Drug Agreements
Trump Health Officials Pledge COVID-19 Vaccine Will Be Free to the 'Vulnerable'
Mandatory HIV Drug Coverage with Employer Health Plans
Employer health plans will be required to fully cover the cost of HIV pre-exposure prophylaxis (PrEP) drugs, effective with plan renewals on and after July 1, 2020. HIV PrEP was issued an “A” recommendation by the U.S. Preventive Services Task Force (USPSTF) in June 2019, as these drugs can reduce the risk of HIV infection for high-risk individuals by 92%, if taken consistently.
Re-Examining the Delivery of High-Value Care Through COVID-19
In this opinion, authors John Rother, Katy Spangler, and V-BID Center Director Mark Fendrick highlight the current opportunity to align incentives for providers and consumers as medical practices and hospitals reopen. Payment policies should drive incentives to improve individual and population health, rather than increase the volume of services delivered.
Low-Value Testing & Imaging Increases Downstream Utilization and May Cost Healthcare Billions
Consumer-Direct Health Plan Enrollment Rises in All Cities over 10 Years, Pushes Physicians to Change Practice
A Scalpel Instead of a Sledgehammer: The Potential Of Value-Based Deductible Exemptions in High-Deductible Health Plans
This Health Affairs blog presents value-based high-deductible plans as a potential solution to flawed high-deductible health plans. Incorporating V-BID principles in HDHPs would include allowing clinical nuance to inform consumer cost-sharing, encouraging the use of high-value care, and limiting the utilization of low-value care.
Crisis Into Opportunity: Can COVID-19 Help Set a Path to Improved Health Care Efficiency?
The COVID-19 pandemic led to an unprecedented decrease in medical visits and procedures, creating a unique opportunity to enhance the efficiency of health care delivery. A recent AJMC commentary, co-authored by V-BID Center Director Mark Fendrick, advocates for investing in high-value services and deterring the resurgence of low-value care as facilities reopen.
Value-Based Insurance Design in Louisiana: Blue Cross Blue Shield's Zero Dollar Co-pay Program
An analysis of Blue Cross Blue Shield of Louisiana’s Zero Dollar Co-pay program found that eliminating pharmacy co-pays for medications related to four chronic diseases led to an 18% decrease in total health spending. This V-BID program focuses on the most at-risk patients and offers a more comprehensive set of medications with no cost-sharing compared to previous studies.
Animated Video: A Clinically Driven Approach - The Value-Based Insurance Design Model
Please Help Support the V-BID Center
As a non-profit entity, the V-BID Center relies on fundraising to support our research, education, and policy efforts. Please help us continue our work by donating here. We truly appreciate your consideration.